Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00733577 · ClinicalTrials.gov registry record · Phase 1
A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00733577 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 48 participants.
The verdict
NCT00733577, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is an escalating dose study in subjects with T2DM, which will consist of four overlapping cohorts receiving 6 days of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics.
Interventions
- DRUG SB756050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-08-11 |
| Est. Completion | 2009-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00733577
The ClinicalTrials.gov registry entry for NCT00733577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB756050 is the first listed.
NCT00733577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00733577 about?
NCT00733577 is a clinical study titled "A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.". This is an escalating dose study in subjects with T2DM, which will consist of four overlapping cohorts receiving 6 days of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics.
What is the current status of trial NCT00733577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-08-11. Estimated completion is 2009-03-03.
What interventions are being tested in trial NCT00733577?
The interventions under investigation include: SB756050 (DRUG).
Who is sponsoring clinical trial NCT00733577?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.